Arrowhead Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Arrowhead Pharmaceuticals

08/08/2025 04:13

Arrowhead Pharmaceuticals Inc ARWR.OQ reported a quarterly adjusted loss of $1.26​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.38.  The mean expectation of fifteen analysts for the quarter was for a loss of $1.03 per share. Wall Street expected results to range from $-1.29 to -29 cents per share.

Revenue was $27.77 million​; analysts expected $23.71 million.

Arrowhead Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.26​.

The company reported a quarterly loss of $175.24 million.

Arrowhead Pharmaceuticals Inc shares had risen by 3.2% this quarter and lost 13.2% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 13% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Arrowhead Pharmaceuticals Inc is $39.50, about 59.3% above its last closing price of $16.06

This summary was machine generated from LSEG data August 8 at 03:13 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-1.03
-1.26
Missed
Mar. 31 2025
-0.20
2.75
Beat
Dec. 31 2024
-0.44
-1.39
Missed
Sep. 30 2024
-1.05
-1.37
Missed